Search

everythinglearnresearchcommunity

for

Search:↓

Hair thinning/loss associated with burning scalp pain. Finasteride helped relieve "DHT itch" for one person.

OP mixed RU58841 with minoxidil and initially saw crystals, but realized they were bubbles. They asked for advice on application frequency for a 5% solution.

Hair loss, Minoxidil, finasteride, and RU58841 as potential treatments for it.

The conversation is about the quality of RU58841 powder from Shaanxi Laon Biotech. The user is inquiring if anyone has experience with this product.

User Crazy-Signature930 shares progress on oral minoxidil for eyelashes and eyebrows. Others comment on the impressive results and ask about side effects and duration of use.

OP experienced diffuse thinning for 11 years and used Minoxidil and Finasteride previously. They now use Pyrilutamide 0.5% and Alfatradiol 0.1%, resulting in significantly reduced hair loss.

Alfatradiol is considered safe but less effective than finasteride for hair loss. One user reported subtle regrowth using alfatradiol with finasteride and minoxidil, while another found alfatradiol ineffective.

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

Alfatradiol is discussed as a weak 5ARI and estrogen, not as effective as minoxidil, RU58841, or CB-03-01, but a safe alternative for those who can't use finasteride. Users express frustration over the lack of strong FDA-approved topical antiandrogens for hair loss.

The conversation is about using alfatradiol (17α-estradiol) as a hair loss treatment. The user is considering adding it to their regimen due to its safety and availability.

The user's experience with rosemary oil as a hair loss treatment and its effectiveness; they discuss other treatments such as finasteride, minoxidil, and RU58841; there is also discussion of combining oils like peppermint oil, zix, and dermapen.

A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

The conversation is about hair loss and the effectiveness of treatments like finasteride, with one user expressing satisfaction after seeing hair regrowth on CCTV. Other users share their experiences with hair visibility and discuss the effectiveness of finasteride compared to dutasteride.

Breezula results are awaited, but no updates have been posted. Users are uncertain about its promise.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

The conversation discusses a user's experiment of "burning the scalp" to treat hair loss, with mixed opinions on its effectiveness. Some suggest returning to proven treatments like finasteride and minoxidil, while others note slight improvements in hair density.

The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.

Minoxidil was applied to a single miniaturized hair follicle over four months, resulting in less miniaturization but not yet terminal growth. The user used a 5% minoxidil solution, specifically the Regaine brand, and observed changes using a handheld WiFi microscope.

The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

User experienced side effects from oral finasteride and tried topical Alfatradiol for hair loss. Alfatradiol provided maintenance without significant regrowth, and user suggests it as an alternative for those struggling with finasteride side effects.

Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.

A user is seeking advice on purchasing RU58841 from Biolab Shop in Poland and is looking for trustworthy sources that deliver to Germany from Europe or China. They are interested in the product's composition and user experiences.

Hair density and color improved with 1mg oral finasteride, 3mg oral minoxidil, red light therapy, biotin, and microneedling. Visible results seen in 3 months.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.

The conversation discusses a user's impressive hair regrowth progress over 17 months using a topical minoxidil and finasteride spray from HIMS, with suggestions to add microneedling for better results. Some users express skepticism about the authenticity of the results, while others inquire about side effects and application methods.